المؤلفون: Ursa Brown-Glaberman, Maaike de Boer, Denise A. Yardley, Jeffrey L. Nordstrom, Sung Bae Kim, Erik Jakobsen, Jean Marc Ferrero, Scott Koenig, William J. Gradishar, Seock-Ah Im, Javier Cortes, Gail S. Wright, Ezio Bonvini, Cristina Saura, Michelino De Laurentiis, Bella Kaufman, Sutton Edlich, Hope S. Rugo, Christelle Levy, Fatima Cardoso, Antonino Musolino, Peter A. Fasching, Mark D. Pegram, Orit Freedman, Santiago Escrivá-de-Romaní, Shengyan Hong, Rinat Yerushalmi, Edwin P. Rock, Giuseppe Curigliano, Katarína Petráková

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Rugo, H. S., Im, S. -A., Cardoso, F., Cortes, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escriva-De-Romani, S., De Laurentiis, M., Levy, C., Brown-Glaberman, U., Ferrero, J. -M., De Boer, M., Kim, S. -B., Petrakova, K., Yardley, D. A., Freedman, O., Jakobsen, E. H., Kaufman, B., Yerushalmi, R., Fasching, P. A., Nordstrom, J. L., Bonvini, E., Koenig, S., Edlich, S., Hong, S., Rock, E. P., Gradishar, W. J., Institut Català de la Salut, [Rugo HS] University of California San Francisco Helen Diller Family Comprehensive Cancer Center. [Im SA] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. [Cardoso F] Champalimaud Clinical Center/Champalimaud Foundation, Breast Unit, Lisbon, Portugal. [Cortés J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Curigliano G] European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milano, Milan, Italy. [Musolino A] Department of Medicine and Surgery, University of Parma, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. [Saura C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: SOPHIA Study Group 2021, ' Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer : A Phase 3 Randomized Clinical Trial ', JAMA Oncology, vol. 7, no. 4, pp. 573-584 . https://doi.org/10.1001/jamaoncol.2020.7932Test
JAMA Oncology, 7(4), 573-584. American Medical Association
JAMA Oncol
Scientia

مصطلحات موضوعية: Oncology, Relative risk reduction, Cancer Research, MONOCLONAL-ANTIBODY, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Ado-Trastuzumab Emtansine, RECOMMENDATIONS, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Original Investigation, Aged, 80 and over, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], benefit, Hazard ratio, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Antibodies, Monoclonal, Middle Aged, CHEMOTHERAPY, Chemotherapy regimen, 030220 oncology & carcinogenesis, Female, Pertuzumab, medicine.drug, Adult, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Breast Neoplasms, IMMUNITY, survival, Quimioteràpia combinada, 03 medical and health sciences, Breast cancer, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, medicine, Humans, Aged, C RECEPTOR POLYMORPHISMS, therapy, business.industry, association, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Interim analysis, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beae17ac62d0e63c250dbce6359002edTest
https://doi.org/10.1001/jamaoncol.2020.7932Test

المؤلفون: Sylvie Le Mouhaer, Mark Clemons, Walter Jonat, Laurence Bourdeau, Barbara Pistilli, Javier Cortes, Carlos L. Arteaga, Dalila Sellami, Banu Sankaran, Yoshinori Ito, Sara A. Hurvitz, Ling Min Tseng, Seock–Ah –A Im, Ahmad Awada, José Baselga, Mona El-Hashimy, Stephen Chia, Zefei Jiang, Mario Campone, Agnieszka Jagiełło-Gruszfeld, Norikazu Masuda, Hiroji Iwata, Michele De Laurentiis

المساهمون: Campone, M., Im, S. -A., Iwata, H., Clemons, M., Ito, Y., Awada, A., Chia, S., Jagiello-Gruszfeld, A., Pistilli, B., Tseng, L. -M., Hurvitz, S., Masuda, N., Cortes, J., De Laurentiis, M., Arteaga, C. L., Jiang, Z., Jonat, W., Le Mouhaer, S., Sankaran, B., Bourdeau, L., El-Hashimy, M., Sellami, D., Baselga, J.

المصدر: European Journal of Cancer. 103:147-154

مصطلحات موضوعية: 0301 basic medicine, Oncology, Morpholine, Cancer Research, medicine.medical_specialty, Morpholines, Population, Buparlisib, Aminopyridines, Breast Neoplasms, Placebo, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Double-Blind Method, Internal medicine, Statistical significance, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Overall survival, education, Adverse effect, Fulvestrant, education.field_of_study, Antineoplastic Combined Chemotherapy Protocol, Hormone receptor-positive breast cancer, business.industry, Cancer, ctDNA, PIK3CA, Middle Aged, medicine.disease, Survival Analysis, Postmenopause, Aminopyridine, 030104 developmental biology, chemistry, Hormone receptor, 030220 oncology & carcinogenesis, Female, business, Breast Neoplasm, Human, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4de6dea03664991c98fc5c9f269298b4Test
https://doi.org/10.1016/j.ejca.2018.08.002Test

المؤلفون: Xavier Pivot, Michelle Miller, Seock-Ah Im, Francisco J. Esteva, Yingbo Wang, Miguel Martin, Arnd Nusch, Luis de la Cruz-Merino, Karen Rodriguez Lorenc, Patrick Neven, Dennis J. Slamon, K. Petrakova, Peter A. Fasching, J. Thaddeus Beck, Stephen Chia, Michelino De Laurentiis, Gena Vidam, Guy Jerusalem, Giulia Val Bianchi, Gabe S. Sonke, Tetiana Taran

المساهمون: Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. -A., Petrakova, K., Val Bianchi, G., Esteva, F. J., Martin, M., Nusch, A., Sonke, G. S., De La Cruz-Merino, L., Beck, J. T., Pivot, X., Vidam, G., Wang, Y., Lorenc, K. R., Miller, M., Taran, T., Jerusalem, G.

المصدر: Journal of Clinical Oncology. 36:2465-2472

مصطلحات موضوعية: Adult, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Receptor, ErbB-2, Aminopyridines, Anastrozole, Breast Neoplasms, Kaplan-Meier Estimate, Palbociclib, Gene mutation, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Progression-free survival, Fulvestrant, Purine, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocol, business.industry, Goserelin, Middle Aged, medicine.disease, Metastatic breast cancer, Progression-Free Survival, Aminopyridine, 030104 developmental biology, Receptors, Estrogen, Purines, 030220 oncology & carcinogenesis, Hormonal therapy, Female, Receptors, Progesterone, business, Breast Neoplasm, Human, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5fd49962d219aec82400b1e61f8756Test
https://doi.org/10.1200/jco.2018.78.9909Test

المؤلفون: Christian Jackisch, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Mahesh Shivhare, Ramon Colomer, Kyung Hae Jung, Tanja Badovinac Crnjevic, Alexandra Hogea, Daniil Stroyakovskii, Sarah Heeson, Antoinette R. Tan, Zbigniew Nowecki, André Mattar, Whitney P. Kirschbrown, Christian Schem, Eleonora Restuccia

المساهمون: Tan, A. R., Im, S. -A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., De Laurentiis, M., Pierga, J. -Y., Jung, K. H., Schem, C., Hogea, A., Badovinac Crnjevic, T., Heeson, S., Shivhare, M., Kirschbrown, W. P., Restuccia, E., Jackisch, C.

المصدر: The Lancet. Oncology. 22(1)

مصطلحات موضوعية: 0301 basic medicine, Adult, medicine.medical_specialty, Time Factors, Receptor, ErbB-2, medicine.medical_treatment, Injections, Subcutaneous, Population, Phases of clinical research, Hyaluronoglucosaminidase, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Loading dose, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, Humans, education, Neoadjuvant therapy, Neoplasm Staging, education.field_of_study, business.industry, Middle Aged, medicine.disease, Chemotherapy regimen, Neoadjuvant Therapy, 030104 developmental biology, Treatment Outcome, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Pertuzumab, business, Febrile neutropenia, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99e575a2761394ec388f6b5a6dee91bfTest
https://pubmed.ncbi.nlm.nih.gov/33539750Test

المؤلفون: Haiying Liu, Sanne de Haas, Seock-Ah Im, Francisco J. Esteva, Jigna Shah, Sherene Loi, Monika Patre, C. Lambertini, Sung Bae Kim, Yifan Wang, Mark Beresford, Aruna Mani, Leisha A. Emens, Roberto Salgado, Cristina Saura, Michelino De Laurentiis

المساهمون: Emens, L. A., Esteva, F. J., Beresford, M., Saura, C., De Laurentiis, M., Kim, S. -B., Im, S. -A., Wang, Y., Salgado, R., Mani, A., Shah, J., Lambertini, C., Liu, H., de Haas, S. L., Patre, M., Loi, S.

المصدر: The Lancet. Oncology. 21(10)

مصطلحات موضوعية: 0301 basic medicine, Male, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Receptor, ErbB-2, Population, Programmed Cell Death 1 Receptor, Phases of clinical research, Breast Neoplasms, Placebo, Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, Double-Blind Method, Atezolizumab, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, education, Adverse effect, education.field_of_study, business.industry, Middle Aged, medicine.disease, Metastatic breast cancer, Survival Analysis, 030104 developmental biology, Treatment Outcome, Oncology, chemistry, Trastuzumab emtansine, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6df8ea55582f078b15ed0a54a5bdc723Test
https://pubmed.ncbi.nlm.nih.gov/33002436Test

المؤلفون: Giulia Val Bianchi, Xavier Pivot, Guy Jerusalem, Luis de la Cruz-Merino, Stephen Chia, Tetiana Taran, Gabe S. Sonke, Seock-Ah Im, Arnd Nusch, Francisco J. Esteva, Patrick Neven, J. Thaddeus Beck, Michelino De Laurentiis, Miguel Martin, Arunava Chakravartty, Dennis J. Slamon, K. Petrakova, Yingbo Wang, Karen Rodriguez-Lorenc, Manu Sondhi, Peter A. Fasching

المساهمون: Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. -A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martin, M., Nusch, A., Sonke, G. S., De La Cruz-Merino, L., Beck, J. T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., Taran, T., Jerusalem, G.

مصطلحات موضوعية: Oncology, medicine.medical_specialty, medicine.drug_class, Receptor, ErbB-2, Aminopyridines, Ribociclib, Breast Neoplasms, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Drug Administration Schedule, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Overall survival, Humans, 030212 general & internal medicine, Progression-free survival, Fulvestrant, Purine, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Cancer, General Medicine, Middle Aged, medicine.disease, Progression-Free Survival, Clinical trial, Postmenopause, Aminopyridine, Receptors, Estrogen, Estrogen, Purines, Female, business, Receptors, Progesterone, Breast Neoplasm, medicine.drug, Human

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba7b985d7c2eab2c811a010405df43eTest
http://hdl.handle.net/11588/804127Test

المؤلفون: Keun Seok Lee, Louis W.C. Chow, Joohyuk Sohn, Debu Tripathy, Seock-Ah Im, Saúl Campos-Gómez, Mei Ching Liu, Paul Wheatley-Price, Aditya Bardia, K Govind Babu, Yen-Shen Lu, Rafael Villanueva Vazquez, Fabio Franke, Sara A. Hurvitz, Samit Hirawat, C. Germa, Gary Carlson, Kyung Hae Jung, I Diaz-Padilla, Young-Hyuck Im, Sherko Kuemmel, Nadia Harbeck, Gareth Hughes, Nagi S. El-Saghir, Michelino De Laurentiis, Marco Colleoni

المساهمون: Tripathy, D., Im, S. -A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Villanueva Vazquez, R., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y. -H., Kuemmel, S., El-Saghir, N., Liu, M. -C., Carlson, G., Hughes, G., Diaz-Padilla, I., Germa, C., Hirawat, S., Lu, Y. -S.

المصدر: The Lancet Oncology. 19:904-915

مصطلحات موضوعية: Adult, 0301 basic medicine, medicine.medical_specialty, Internationality, Antineoplastic Agents, Hormonal, medicine.drug_class, Administration, Oral, Aminopyridines, Breast Neoplasms, Kaplan-Meier Estimate, Placebo, Disease-Free Survival, Drug Administration Schedule, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm Invasiveness, Neoplasm Staging, Proportional Hazards Models, Aromatase inhibitor, Dose-Response Relationship, Drug, business.industry, Letrozole, Goserelin, Cancer, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Tamoxifen, Treatment Outcome, 030104 developmental biology, Premenopause, Oncology, Purines, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bccb67927d7e7197be33f1a10ad14c71Test
https://doi.org/10.1016/s1470-2045Test(18)30292-4